Fahar and Rosemina Merchant’s Medicenna targets brain cancer with molecular Trojan horse

Source: BioTuesdays

Fahar and Rosemina Merchant's Medicenna targets brain cancer with molecular Trojan horseMedicenna Therapeutics (TSXV:MDNA) is advancing a targeted dual-action immunotherapeutic, MDNA55, that consists of an engineered version of interleukin-4 (IL-4) plus a tumor-killing cytotoxin for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.

“Cancer cells proliferate with the help of IL-4, so our approach is to trick the cell to ingest our toxin-laden IL-4 Empowered Cytokines, which makes MDNA55 a powerful Trojan horse,” Fahar Merchant, chairman, president and CEO, says in an interview with BioTuesdays.

“Because MDNA55 is so targeted and so potent, we don’t need to use much of the drug,” he adds, noting that one-gram of MDNA55 is enough to treat 10,000 patients.

Medicenna, which is derived by combining the word, medicine, with Avicenna, the father of evidence-based medicine, is currently enrolling patients in a Phase 2b study, which if successful, could lead to an application for accelerated approval of MDNA55 for patients with recurrent glioblastoma.

Dr. Merchant explains that MDNA55 enters a cancer cell by binding to the IL-4 receptor on the cell surface and, after entering the cell, initiates apoptosis, or cell death.

Read more – Dated: June 06, 2017

 

Previously on Ismailimail…

Author: ismailimail

Independent, civil society media featuring Ismaili Muslim community, its achievements and humanitarian works.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s